Home › Funds › Grantham, Mayo, Van Otterloo & Co. LLC › ABT

Grantham, Mayo, Van Otterloo & Co. LLC position in ABT

ABBOTT LABORATORIES · Health Care

Grantham, Mayo, Van Otterloo & Co. LLC reported holding 8,966,588 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$886.2M, representing 1.90% of its reported portfolio and ranking #16 among its reported holdings. Grantham, Mayo, Van Otterloo & Co. LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)8.97M sh
Reported value held$886.17M
Portfolio Weight1.90%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Grantham, Mayo, Van Otterloo & Co. LLC's ABT position evolved

Grantham, Mayo, Van Otterloo & Co. LLC first disclosed a stake in ABT in Q3 2023 at 3,664,856 shares (US$354.9M). The position peaked in Q3 2025 at 8,176,484 shares, worth US$1.10B. Across 13 filings, Grantham, Mayo, Van Otterloo & Co. LLC increased the stake 10 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 8,966,588 shares valued at US$886.2M — an increase of 172,511 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.66M $354.94M New
Q4 2023 4.38M $481.60M Add
Q1 2024 5.41M $614.67M Add
Q2 2024 5.79M $601.86M Add
Q3 2024 7.11M $810.58M Add
Q4 2024 7.90M $893.22M Add
Q1 2025 8.11M $1.08B Add
Q2 2025 7.81M $1.06B Reduce
Q3 2025 8.18M $1.10B Add
Q4 2025 8.48M $1.06B Add
Q1 2026 8.91M $914.89M Add
Q2 2026 8.79M $797.97M Reduce
Q3 2026 8.97M $886.17M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Grantham, Mayo, Van Otterloo & Co. LLC held ABT?

Grantham, Mayo, Van Otterloo & Co. LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Grantham, Mayo, Van Otterloo & Co. LLC's current position in ABT?

As of Q3 2026, Grantham, Mayo, Van Otterloo & Co. LLC holds 8.97M shares of ABT (ABBOTT LABORATORIES), valued at $886.17M, representing 1.90% of its reported portfolio and ranking #16.

Has Grantham, Mayo, Van Otterloo & Co. LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), Grantham, Mayo, Van Otterloo & Co. LLC increased its position in ABT. The position peaked in Q3 2025 at 8.18M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.